Latest Revenue Growth News

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Adrad Holdings reported an 8.9% rise in FY25 sales revenue to $153.1 million despite a slight dip in EBITDA, while declaring a fully franked dividend and outlining strategic initiatives for FY26.

Adrad Holdings reported solid FY25 results with revenue climbing 8.9% to $153.1 million, despite a slight dip in EBITDA due to cost pressures. The company boosted its dividend by 18%, reflecting confidence in future growth.

Amaero Ltd reported a 470% revenue surge to $3.8 million for FY2025, driven by expanded production capacity and exclusive supply deals, while continuing to invest heavily in infrastructure and operations, resulting in a $24.4 million loss.

Audinate reported a 33% revenue decline in FY25 due to OEM inventory adjustments but boosted gross margins to 82.1% through a software shift and completed the strategic Iris acquisition, setting the stage for growth in FY26.

AML3D Limited reported a modest increase in revenue for FY2025 but saw its losses widen significantly, raising questions about its path to profitability.

GWA Group Limited reported modest revenue and earnings growth for FY2025, underpinned by strong Australian and UK markets, while announcing a $30 million on-market share buyback starting September 2025.

GWA Group Limited has reported a solid FY25 financial performance with modest revenue and profit growth, alongside a dividend increase and a new $30 million share buyback program.

GWA Group Limited reported modest revenue and profit growth for FY2025, driven by disciplined execution amid challenging markets. The company raised its dividend and announced a $30 million on-market share buyback, underscoring confidence in its financial position.

Aurizon reported a slight decline in FY2025 underlying EBITDA to $1.576 billion but secured a landmark BHP contract and announced a fresh $150 million buy-back, signaling confidence in its future growth.

Fiducian Group reported robust FY2025 results, showcasing significant growth in funds under management and administration alongside a strong dividend payout. The company’s fintech innovation and adviser expansion underpin its steady momentum.

Fiducian Group Limited has reported a solid 23.5% rise in net profit for the 2025 financial year, alongside a 10.6% increase in revenue and a higher fully franked final dividend of 24.7 cents per share.